Skip to main content
Nature Communications logoLink to Nature Communications
. 2020 Jul 31;11:3913. doi: 10.1038/s41467-020-17748-7

Author Correction: Jawsamycin exhibits in vivo antifungal properties by inhibiting Spt14/Gpi3-mediated biosynthesis of glycosylphosphatidylinositol

Yue Fu 1,#, David Estoppey 2,#, Silvio Roggo 2,#, Dominik Pistorius 2,#, Florian Fuchs 2,#, Christian Studer 2,#, Ashraf S Ibrahim 3,4, Thomas Aust 2, Frederic Grandjean 2, Manuel Mihalic 2, Klaus Memmert 2, Vivian Prindle 1, Etienne Richard 2, Ralph Riedl 2, Sven Schuierer 2, Eric Weber 2, Jürg Hunziker 2, Frank Petersen 2, Jianshi Tao 1,, Dominic Hoepfner 2,
PMCID: PMC7395079  PMID: 32737318

Correction to: Nature Communications10.1038/s41467-020-17221-5, published online 7 July 2020.

The original version of this Article omitted the following from the Acknowledgements:

We also thank the Novartis Chemical & Pharmaceutical Profiling & DMPK teams for their support on evaluation of in vivo efficacy of Jawsmycin.

This has now been corrected in both the PDF and HTML versions of the Article.

Contributor Information

Jianshi Tao, Email: jtao@gnf.org.

Dominic Hoepfner, Email: dominic.hoepfner@novartis.com.


Articles from Nature Communications are provided here courtesy of Nature Publishing Group

RESOURCES